Vakaramoko "Karam" Diaby, Ph.D. M.Sc.


Assistant Professor

Department of Pharmaceutical Outcomes & Policy



PHONE: (352) 273-9397

CV: Link to CV



  • Ph.D., Pharmaceutical Sciences: Drug and Population Health, University of Montreal, College of Pharmacy
  • M.Sc., Pharmaceutical Sciences: Drug and Population Health, University of Montreal, College of Pharmacy

Biographical Sketch

Vakaramoko “Karam” Diaby received his Ph.D. in 2011 from the College of Pharmacy at the University of Montreal (Quebec, Canda).   Dr. Diaby holds a Clinical Research Associate Certification from Sup Santé Paris (France), an MSc and a PhD in Pharmaceutical Sciences from the University of Montreal, Canada. He was also a Post-Doctoral Fellow at the Programs for Assessment of Technology in Health (PATH) Research Institute, McMaster University, Hamilton, Canada.  Dr. Diaby is a former Assistant Professor of Pharmaceutical Sciences at the College of Pharmacy and Pharmaceutical Sciences (COPPS) at Florida A&M University. His main research interests are in the field of Economic Evaluation, Health Technology Assessment (HTA) and priority setting using Multi-Criteria Decision Analysis (MCDA). He is also interested in decision analytic modeling.

Research Interests

  • Economic Evaluation
  • Health Technology Assessment (HTA)
  •  Pharmacoeconomics (Oncology)/Decision analytic modeling
  •  Priority setting using Multi-Criteria Decision Analysis (MCDA)
  •  Policy evaluations

Recent Publications

Askal Ayalew Ali, Hong Xiao, Rima Tawk, Ellen Campbell, Anastasia Semykina, Alberto J Montero, Vakaramoko Diaby. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Current medical research and opinion.

Boulin M, Diaby V, Tannembaum C. (2016). Preventing unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada. PloS one 11.9 (2016): e0162951.

Diaby V, Adunlin G, Ali A, Lopes G, Zeichner S, Kohn C, Montero A. (2016). Cost-effectiveness of treatment sequencing for metastatic HER2-positive breast cancer patients. Breast Cancer Research and Treatment. 160.1: 187-196.

Diaby, V., Ali, A. A., Adunlin, G., Kohn, C. G., & Montero, A. J. (2016). Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Current medical research and opinion, 1-6.

Askal Ayalew Ali, Hong Xiao, Ellen S. Campbell, Vakaramoko Diaby. (2016). Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation. Pharm Med. DOI 10.1007/s40290-015-0113-7.

Vakaramoko Diaby, Vassiki Sanogo, Kouame Richard Moussa. (2016). ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare. Expert review of pharmacoeconomics & outcomes research. DOI:10.1586/14737167.2015.1083863.

Tannenbaum, C., Diaby, V., Singh, D., Perreault, S., Luc, M., & Vasiliadis, H. M. (2015). Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs & aging, 32(4), 305-314.

Diaby, V., Tawk, R., Sanogo, V., Xiao, H., & Montero, A. J. (2015). A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast cancer research and treatment, 151(1), 27-40.

Adunlin, Georges, Vakaramoko Diaby, and Hong Xiao. “Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis.” Health Expectations (2014).

Diaby, V., Goeree R, Hoch, J., Siebert, U. Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Canada: Insights from an expert panel discussion Expert review of pharmacoeconomics & outcomes research 15.1 (2014): 13-19.

Diaby, V., Adunlin, G., Ali, A. A., & Tawk, R. (2014). Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast cancer research and treatment, 146(3), 669-673.

Diaby, V., Adunlin, G., Zeichner, S. B., Avancha, K., Lopes, G., Gluck, S., & Montero, A. J. (2014). Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast cancer research and treatment, 1-9.

Diaby, V., Adunlin, G., & Montero, A. J. (2014). Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial. PharmacoEconomics, 32(2), 101-108.

Adunlin, G., Diaby, V, Montero, A. J., & Xiao, H. (2014). Multicriteria decision analysis in oncology. Health Expect. 2014 Mar 17. doi: 10.1111/hex.12178. [Epub ahead of print].

Diaby, V., & Goeree, R. (2014). How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. Expert review of pharmacoeconomics & outcomes research, 14(1), 81-99.

Goeree, R., & Diaby, V. (2013). Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? Best Practice & Research Clinical Gastroenterology, 27(6), 831-844.

Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, Kind P, Goetghebeur MM, International Task Force on Decision Criteria (including: Ferraz MB, Carrasqueiro S, Chinitz D, Chitama D, Clifford T, Cumming J, Diaby V, Flamion B, Gerber-Grote A, Goeree R, Guindo A, Harstall C, Jacobs P, Jehu-Appiah C, Kletchko S, Lettieri E, Longworth L, Martin J, McDonald K, Miot J, Niessen L, Paolucci F, Peacock S, Poulin P, Raisch DW, Rajasekaran S, Ryan F, Siebert U, Tringali M, Waldau S, Wong P). Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers [In Press]. Int J Technol Assess Health Care 2013.

Adunlin, G., Xiao, H., & Diaby, V. (2013). Exploring the state of pharmacy profession: The perspective of Côte d’Ivoire. Currents in Pharmacy Teaching and Learning, 5(5), 470-476.

Diaby, V., Campbell, K., & Goeree, R. (2013). Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis. Operations Research for Health Care, 2(1), 20-24.

Diaby, V., & Lachaine, J. (2011). An application of a proposed framework for formulary listing in low-income countries. Applied health economics and health policy, 9(6), 389-402.

Diaby, V., Kakou, H. D., & Lachaine, J. (2011). Eliciting preferences for reimbursed drugs selection criteria in Côte d’Ivoire. The Patient: Patient-Centered Outcomes Research, 4(2), 125-131.

Diaby,V., Laurier, C., & Lachaine, J. (2011). A proposed framework for formulary listing in low-income countries. Pharmaceutical Medicine, 25(2), 71-82.

Diaby V, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. Maturitas. 2007 Oct 20;58(2):138-49. Epub 2007 Sep 17.